



Universal Xalqaro Ilmiy Jurnal

Jurnalning bosh sahifasi: <https://universaljurnal.uz>

Universal International Scientific
Journal

e-ISSN: [3060-4540 \(online\)](https://universaljurnal.uz)

Year: 2025 Issue: 2 Volume: 1

Published: 08.01.2025
<https://universaljurnal.uz>



International indexes

GOOGLE SCHOLAR
CROSSREF (OAK BAZA)
ZENODO
OPEN AIRE
EUROPUB
RESEARCHGATE (OAK BAZA)
SJIF

CLINICAL FEATURES AND TREATMENT OF UROGENITAL DIABETIC AUTONOMIC NEUROPATHY

Pirmatov Shakhbozbek Shukhratbek ugli

Assistant of Department of Epidemiology and Infectious Diseases

FMIOPH

Uzbekistan

pirmatovshaxbozbek@gmail.com

<https://orcid.org/0009-0005-5336-6668>

Abstract: The urogenital form of diabetic autonomic neuropathy (DAN) is a common yet underdiagnosed complication of diabetes, severely affecting quality of life. This review covers clinical manifestations like bladder and erectile dysfunction, diagnostic methods, and treatments, including glycemic control, PDE5 inhibitors, neuromodulation, and emerging therapies. Persistent challenges highlight the need for multidisciplinary approaches and further research into personalized strategies.

Keywords: diabetic autonomic neuropathy (DAN), urogenital dysfunction, bladder dysfunction, erectile dysfunction, neurophysiological diagnostics, multidisciplinary treatment.

Annotatsiya: Diabetik vegetativ neyropatiyaning (DVN) urogenital shakli diabetning keng tarqalgan, ammo tashxislanmagan asorati bo'lib, hayot sifatiga jiddiy ta'sir qiladi. Ushbu sharhda siydik pufagi va erektil disfunktsiyasi, diagnostika usullari va davolash usullari, jumladan glikemik nazorat, PDE5 ingibitorlari, neyromodulyatsiya va rivojlanayotgan terapiya kabi klinik ko'rinishlar yoritilgan. Doimiy

muammolar ko'p tarmoqli yondashuvlar va shaxsiylashtirilgan strategiyalarni yanada tadqiq qilish zarurligini ta'kidlaydi.

Kalit so'zlar: diabetik vegetativ neyropatiya (DAN), urogenital disfunktsiya, siydik pufagi disfunktsiyasi, erektil disfunktsiya, neyrofiziologik diagnostika, ko'p tarmoqli davolash.

Аннотация: Урогенитальная форма диабетической вегетопатии (ДВН) является распространенным, но недостаточно диагностируемым осложнением диабета, серьезно влияющим на качество жизни. Этот обзор охватывает такие клинические проявления, как дисфункция мочевого пузыря и эрекции, методы диагностики и лечения, включая контроль гликемии, ингибиторы PDE5, нейромодуляцию и новую терапию. Постоянные вызовы подчеркивают необходимость multidисциплинарных подходов и дальнейших исследований персонализированных стратегий.

Ключевые слова: диабетическая вегетативная нейропатия (ДВН), уrogenитальная дисфункция, дисфункция мочевого пузыря, эректильная дисфункция, нейрофизиологическая диагностика, многопрофильное лечение.

Language: English

Citation: Pirmatov , S. (2025). CLINICAL FEATURES AND TREATMENT OF UROGENITAL DIABETIC AUTONOMIC NEUROPATHY. Universal International Scientific Journal, 2(1), 59–67.

<https://doi.org/10.69891/3060-4540.2025.39.71.001>

Doi: <https://doi.org/10.5281/zenodo.14711437>

Google scholar: https://scholar.google.com/scholar?hl=ru&as_sdt=0%2C5&q=CLINICAL+FEATURES+AND+TREATMENT+OF+UROGENITAL+DIABETIC+AUTONOMIC+NEUROPATHY&btnG=

Crosreff doi: <https://doi.org/10.69891/3060-4540.2025.39.71.001>

INTRODUCTION.

Diabetic autonomic polyneuropathy (DAN) significantly impacts the urogenital system, manifesting as diabetic bladder dysfunction, sexual dysfunction, and recurrent urinary tract infections, which are more prevalent than other diabetic complications like neuropathy or nephropathy[1]. The prevalence of these conditions is notably high, with over 50% of individuals with diabetes experiencing lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), and up to 39%

of women suffering from urinary incontinence. These dysfunctions are linked to abnormalities in the detrusor muscle, urothelium, and urethra, and are influenced by neurogenic, vasculogenic, hormonal, metabolic, drug-induced, and psychological factors[2]. The UroEDIC study, part of the DCCT/EDIC research, highlighted significant associations between cardiovascular autonomic neuropathy and urologic complications, underscoring the need for comprehensive management strategies[1,3].

Understanding the prevalence and quality-of-life implications of these conditions is crucial, as they severely affect patients' well-being and are often underdiagnosed[4]. Effective clinical management requires a multidisciplinary approach, incorporating lifestyle interventions, pharmacological treatments, and psychological counseling. Recent advancements in antihyperglycemic drugs also show promise in improving sexual function through weight control[2]. Despite these developments, there remains a critical need for further research to enhance diagnostic and treatment protocols, as well as to address the social determinants of health that influence the management of DAN[5].

PATHOPHYSIOLOGY AND EPIDEMIOLOGY.

Diabetic autonomic neuropathy (DAN) is a prevalent complication of diabetes mellitus, affecting multiple systems, including the urogenital system, which leads to significant morbidity. The mechanisms of autonomic nerve damage in diabetes involve microvascular complications that impair nerve function, resulting in a range of dysfunctions across the cardiovascular, gastrointestinal, and urogenital systems[6,7]. In the urogenital system, diabetic autonomic neuropathy manifests as bladder dysfunction, sexual dysfunction, and recurrent urinary tract infections, with both men and women experiencing these complications[1,6]. The pathways specifically affected include

those responsible for erectile function in men and sexual function in women, as well as lower urinary tract symptoms[1]. The prevalence of urogenital diabetic neuropathy is notably high, with studies such as the UroEDIC study highlighting significant associations between cardiovascular autonomic neuropathy and urologic complications in individuals with type 1 diabetes[1,3]. Risk factors for developing these complications include poor glycemic control, longer duration of diabetes, and associated cardiovascular risk factors. Demographically, the prevalence and incidence of autonomic neuropathy, including urogenital manifestations, vary widely due to differences in study populations and diagnostic criteria, but it is clear that these complications are more common in individuals with prolonged diabetes[8]. Understanding these mechanisms and epidemiological factors is crucial for developing effective management and prevention strategies for urogenital diabetic neuropathy.

CLINICAL NEUROLOGICAL FEATURES.

Diabetic autonomic neuropathy (DAN) significantly impacts the urogenital system, manifesting primarily as bladder and sexual dysfunction. Key symptoms of urogenital dysfunction in diabetic autonomic neuropathy include lower urinary tract symptoms (LUTS) such as an overactive or poorly contractile bladder, erectile dysfunction (ED) in men, and

changes in sexual activity and function in women. These symptoms are prevalent, with over 50% of diabetic patients experiencing LUTS and ED, and urinary incontinence affecting up to 39% of women with diabetes[1,2]. The assessment of neurological damage in diabetic patients involves a comprehensive clinical history and physical examination, focusing on autonomic symptoms. Diagnostic tools include questionnaires, bladder diaries, urinalysis, uroflowmetry, and urodynamics for LUTS, while ED evaluation involves medical and sexual history, psychological evaluation, hormone level testing, and cardiovascular autonomic function tests[2,4,9]. Differential diagnoses for urogenital dysfunction in diabetes should consider other potential causes such as neurogenic, vasculogenic, hormonal, metabolic, drug-induced, and psychological factors. Additionally, conditions like amyloidosis, uremic neuropathy, vitamin B12 deficiency, paraneoplastic autonomic neuropathy, HIV infection, and alcoholic neuropathy should be considered, as they can present with similar autonomic symptoms[10,11]. The UroEDIC study highlights the significant association between cardiovascular autonomic neuropathy and urogenital complications, emphasizing the need for a multidisciplinary approach to diagnosis and management[3]. Effective management of these dysfunctions often requires a combination of pharmacological treatments, lifestyle interventions, and

psychological counseling, tailored to the specific symptoms and underlying causes[2,6].

NEUROPHYSIOLOGICAL CHARACTERISTICS.

Urodynamic studies, nerve conduction studies, evoked potential testing, and emerging neurophysiological markers are critical tools in assessing autonomic dysfunction in the urogenital form of diabetic neuropathy. Urodynamic studies are considered the gold standard for evaluating lower urinary tract function in neuro-urological patients, including those with diabetic neuropathy. These studies help identify conditions such as neurogenic detrusor overactivity and detrusor-sphincter dyssynergia, which are crucial for risk stratification and management of urological comorbidities[12,13]. Nerve conduction studies, although limited in diagnosing small-fiber neuropathy, are useful in detecting abnormalities in motor and sensory nerve functions, which can be indicative of diabetic neuropathy[14,15]. Evoked potential testing, such as somatosensory-evoked potentials (SSEP) and sympathetic skin response (SSR), provides non-invasive means to detect early urinary and sexual dysfunction in diabetic patients, offering a significant advantage in early diagnosis[14]. Emerging neurophysiological markers, including cutaneous silent periods (CSPs), have shown promise in diagnosing small-fiber neuropathy, with CSPs demonstrating higher diagnostic utility than traditional

autonomic tests[15]. However, these diagnostic methods have limitations. Urodynamic studies, while comprehensive, are invasive and may not be suitable for all patients[12]. Nerve conduction studies often fail to detect small-fiber neuropathy, which is a common issue in diabetic patients[15]. Evoked potential tests, although non-invasive, may not always correlate with clinical symptoms, leading to potential underdiagnoses[14]. Despite these limitations, these diagnostic tools, when used in conjunction, provide a robust framework for assessing autonomic dysfunction in diabetic neuropathy, guiding therapeutic decisions and improving patient outcomes[16,17].

TREATMENT METHODS.

The treatment of the urogenital form of diabetic autonomic neuropathy (DAN) involves a multifaceted approach that includes both pharmacological and non-pharmacological strategies. Pharmacologically, glycemic control is paramount as it can mitigate the severity of autonomic neuropathy and its complications, including those affecting the urogenital system[18,19]. Phosphodiesterase type 5 (PDE5) inhibitors are the first-line treatment for erectile dysfunction (ED) in men, a common manifestation of urogenital DAN[20,21]. For bladder dysfunction, antimuscarinics or β -3 agonists are recommended for detrusor overactivity, while intermittent catheterization and neuromodulation are used for underactive

bladder[22]. Non-pharmacological strategies include lifestyle modifications such as diet and exercise, which are crucial for glycemic control and overall health improvement[19,23]. Physical therapy and neuromodulation techniques, such as tibial nerve stimulation and sacral neuromodulation, are employed for bladder dysfunction[22]. Emerging therapies are being explored, including stem cell treatments and advanced glycation end-product inhibitors, although these are still in the experimental stages and not yet widely implemented[19]. The management of female sexual dysfunction, often driven by social and psychological factors, requires a multidisciplinary approach, including lifestyle interventions and hormone therapy in postmenopausal women[22]. Despite the availability of these treatments, there remains a significant gap in effective management due to underdiagnosis and limited clinical research, highlighting the need for a comprehensive and multidisciplinary approach to improve outcomes for patients with diabetic urogenital dysfunction[22,24].

CHALLENGES AND FUTURE DIRECTIONS.

Urogenital diabetic autonomic neuropathy (DAN) presents significant unmet needs in both clinical management and research, primarily due to its complex pathophysiology and the challenges associated with early detection. The condition affects the urogenital system,

leading to bladder and sexual dysfunction, which significantly impacts the quality of life for individuals with diabetes[25,26]. Despite its prevalence, there is a widespread underdiagnosis of these dysfunctions, partly due to limited clinical research and knowledge, which hinders effective management[25,27]. Early detection of diabetic neuropathy, including urogenital manifestations, remains challenging due to the often asymptomatic nature of the condition in its initial stages[28,29]. The lack of reliable biomarkers for early neuropathic changes further complicates timely diagnosis and intervention[29]. Current management strategies for urogenital dysfunctions, such as erectile dysfunction and bladder issues, involve a combination of pharmacological treatments, lifestyle interventions, and psychological counseling, yet these are often only partially effective and can be associated with adverse effects[25,26]. Advances in personalized medicine hold promise for addressing these challenges by tailoring treatments to individual patient profiles, potentially improving outcomes. However, the development of such personalized approaches requires a deeper understanding of the genetic, metabolic, and environmental factors contributing to DAN[30,31]. Future therapies may benefit from integrating novel glucose-lowering agents, which have shown potential in reducing cardiovascular events and may indirectly benefit autonomic neuropathy[30]. Additionally, the use of

wearable devices and innovative screening methods could enhance early detection and monitoring, although further research is needed to optimize these technologies[30,32]. Overall, addressing the unmet needs in urogenital diabetic autonomic neuropathy requires a multidisciplinary approach, increased awareness, and continued research into effective diagnostic and therapeutic strategies[25,33]. The management of urogenital diabetic autonomic neuropathy (DAN) presents several challenges. Early detection remains difficult due to the asymptomatic nature of initial stages and a lack of reliable biomarkers. Most diagnostic techniques, such as urodynamic studies and nerve conduction tests, focus on advanced stages of dysfunction, leaving early interventions limited. [34,35]. Additionally, underreporting of symptoms by patients, often due to social stigma or lack of awareness, contributes to underdiagnosis and delayed treatment. Current treatment strategies, while effective in symptom management, often fail to address the progressive nature of autonomic neuropathy[36,37].. Pharmacological approaches, such as PDE5 inhibitors for erectile dysfunction or antimuscarinics for bladder dysfunction, primarily target symptoms rather than underlying nerve damage. Similarly, non-pharmacological methods like neuromodulation and lifestyle interventions, while promising, require further research to optimize protocols and

enhance accessibility[38,39]. Advances in personalized medicine offer hope for tailored treatment options that consider genetic, metabolic, and environmental factors. Innovative therapies, including stem cell applications and advanced glycation end-product inhibitors, show potential but are still in experimental stages. Integrating these approaches with modern screening technologies, such as wearable devices for continuous monitoring, could significantly improve early detection and long-term outcomes. Despite these advancements, gaps in research and clinical practice persist, particularly in addressing the psychosocial aspects of urogenital dysfunction. Comprehensive, multidisciplinary care involving endocrinologists, urologists,

neurologists, and mental health professionals is essential to tackle the multifaceted impact of urogenital DAN and improve patient outcomes[40].

CONCLUSION.

Urogenital diabetic autonomic neuropathy is a significant complication of diabetes that profoundly affects patient well-being. Early diagnosis using advanced neurophysiological tools and a combination of pharmacological and non-pharmacological treatments are essential for effective management. However, persistent challenges in detection and therapy highlight the need for greater awareness, multidisciplinary strategies, and continued research into innovative treatment modalities.

REFERENCES:

1. Nnenaya Agochukwu-Mmonu et al. Autonomic neuropathy and urologic complications in diabetes. // *Autonomic Neuroscience: Basic and Clinical*. 2020. Vol. 229. P. 102736–102736.
2. Maria Raineri. Diabetic Neuropathy: Clinical Management—Genitourinary Dysfunction in Diabetes. 2023. P. 491–529.
3. Barbara H. Braffett, Hunter Wessells, Aruna V. Sarma. Urogenital Autonomic Dysfunction in Diabetes // *Current Diabetes Reports*. 2016. Vol. 16, № 12. P. 119–119.
4. Aaron I. Vinik et al. Neurological Disease and Diabetes, Autonomic. 2004. P. 334–339.
5. Rodica Pop-Busui. Autonomic diabetic neuropathies: A brief overview. // *Diabetes Research and Clinical Practice*. 2023. Vol. 206 Suppl 1. P. 110762–110762.
6. Anastasios Tentolouris, Nikolaos Tentolouris. Diabetic Autonomic Neuropathy. 2021. P. 307–315.
7. Roy Freeman. Diabetic autonomic neuropathy. // *Handbook of Clinical Neurology*. 2014. Vol. 126. P. 63–79.
8. Rodica Pop-Busui, Andrew J.M. Boulton, Jay M. Sosenko. Peripheral and Autonomic Neuropathy in Diabetes. 2018.
9. Chong Hwa Kim. Diagnosis and Management of Diabetic Autonomic Neuropathy // *The Journal of Korean Diabetes*. 2018. Vol. 19, № 3. P. 160–167.
10. Juan Idiaquez, Eduardo E. Benarroch, Martin Nogues. Autonomic Failure in Chronic Peripheral Neuropathy. 2018. P. 73–86.
11. Takashi Ito et al. Urinary dysfunction and autonomic control in amyloid neuropathy // *Clinical Autonomic Research*. 2006. Vol. 16, № 1. P. 66–71.
12. Andry Perrin, Jacques Corcos. The Utility of Urodynamic Studies in Neuro-Urological Patients // *Advances in Cardiovascular Diseases*. 2023. Vol. 11, № 4. P. 1134–1134.

13. Hazel Ecclestone, Rizwan Hamid. Clinical Neuro-uropsychological Investigations. 2018. P. 181–189.
14. Hanan El Sebaie El Hefnawy et al. Evaluation of different electrophysiological studies in the detection of urinary and sexual dysfunction in diabetic women // Egyptian Rheumatology and Rehabilitation. 2013. Vol. 40, № 1. P. 39–49.
15. Pinar Kahraman Koysak et al. Assessment of symptomatic diabetic patients with normal nerve conduction studies: utility of cutaneous silent periods and autonomic tests. // Muscle & Nerve. 2011. Vol. 43, № 3. P. 317–323.
16. Guillaume Lamotte, Paola Sandroni. Updates on the Diagnosis and Treatment of Peripheral Autonomic Neuropathies // Current Neurology and Neuroscience Reports. 2022. Vol. 22, № 12. P. 823–837.
17. Charushila Atul Rukadikar, Atul R. Rukadikar, Surekha Kishore. A Review on Autonomic Functional Assessment in Diabetic Patients // Cureus. 2023. Vol. 15, № 2. P. e34598–e34598.
18. David S.H. Bell. Detecting and treating the protean manifestations of diabetic autonomic neuropathy // Diabetes, Obesity and Metabolism. 2023. Vol. 25. P. 1162–1173.
19. Strategies for the prevention or reversal of neuropathy. 2022. P. 259–281.
20. Anastasios Tentolouris, Nikolaos Tentolouris. Diabetic Autonomic Neuropathy. 2021. P. 307–315.
21. Dan Ziegler. Autonome diabetische Neuropathie // Diabetologe. 2020. Vol. 16, № 3. P. 315–326.
22. Maria Raineri. Diabetic Neuropathy: Clinical Management—Genitourinary Dysfunction in Diabetes. 2023. P. 491–529.
23. Alaka Deshpande. Diabetic Autonomic Neuropathy // Journal of the Medical Sciences. 2018. Vol. 5, № 2. P. 85–87.
24. Nnenaya Agochukwu-Mmonu et al. Autonomic neuropathy and urologic complications in diabetes. // Autonomic Neuroscience: Basic and Clinical. 2020. Vol. 229. P. 102736–102736.
25. Maria Raineri. Diabetic Neuropathy: Clinical Management—Genitourinary Dysfunction in Diabetes. 2023. P. 491–529.
26. Anastasios Tentolouris, Nikolaos Tentolouris. Diabetic Autonomic Neuropathy. 2021. P. 307–315.
27. Ogli N.A.K., Qahhorali G. IMPROVEMENT OF SURGICAL TACTICS AND TREATMENT OF COMBINED INJURIES IN CHILDREN: 5–2 // Eurasian Journal of Medical and Natural Sciences. Республика Узбекистан, Ташкент: ООО «Innovative Academy RSC», 2024. Vol. 4, № 5–2. P. 17–21.
28. Advances in screening, early diagnosis, and accurate staging of diabetic neuropathy. 2022. P. 47–78.
29. Josie Carmichael et al. Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy. // Frontiers in Endocrinology. 2021. Vol. 12. P. 671257–671257.
30. Aikaterini Eleftheriadou et al. Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management // Diabetologia. 2024.
31. Lynn Ang et al. The conundrum of diabetic neuropathies-Past, present, and future. // Journal of Diabetes and Its Complications. 2022. Vol. 36, № 11. P. 108334–108334.
32. Salem Beshyah et al. Current Perspectives in Pre- and Diabetic Peripheral Neuropathy Diagnosis and Management: An Expert Statement for the Gulf Region // Diabetes Therapy. 2024.
33. Prawej Ansari et al. Challenges in Diabetic Micro-Complication Management: Focus on Diabetic Neuropathy // International Journal of Technology Management. 2021. Vol. 1, № 3. P. 175–186.
34. Shuxrat o'g'li P. S. EEG CHARACTERISTICS OF DIFFERENT TYPES OF FOCAL EPILEPSY IN ADULT PATIENTS // Web of Medicine: Journal of Medicine, Practice and Nursing. – 2023. – T. 1. – №. 9. – С. 1-3.

35. Жураев, С. Б. ОПТИМИЗАЦИЯ ТАКТИКИ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ ПОВРЕЖДЕНИЙ АРТЕРИЙ КОНЕЧНОСТЕЙ ПРИ СОЧЕТАННЫХ ТРАВМАХ. «YOSH OLIMLAR TIBBIYOT JURNALI» TASHKENT MEDICAL ACADEMY «MEDICAL JOURNAL OF YOUNG SCIENTISTS» ТАШКЕНТСКАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ, 82.
36. Jurayev S.B. (2024). CURRENT TREATMENT OPTIONS OF ADHESIVE SMALL BOWEL OBSTRUCTION (LITERATURE REVIEW). <https://doi.org/10.5281/zenodo.14506496>
37. Abdurakhmonov, N. (2024). THE IMPORTANCE OF DIFFERENTIAL DIAGNOSING IN TREATMENT OF MARGINAL BLEPHARITIS WITH DEMODEX ETIOLOGY. Science and innovation, 3(D5), 188-192.
38. O'gli P. S. S. KATTA YOSHLI BEMORLARDA FOKAL EPILEPSIYANI TURLI XILLIGINI EEG XUSUSIYATLARI //Ta'lim fidoyilari. – 2022. – Т. 5. – №. 9. – С. 621-624.
39. Niyozbek Abdurakhmonov Khamdamjon Ogli, & Gulomov Qahhorali (2024). IMPROVEMENT OF SURGICAL TACTICS AND TREATMENT OF COMBINED INJURIES IN CHILDREN. Eurasian Journal of Medical and Natural Sciences, 4 (5-2), 17-21. doi: 10.5281/zenodo.11367251
40. Пирматов Ш.Ш., Рахматуллаева Н.И., & Холматов Р.И. (2021). ОСОБЕННОСТИ ЭЭГ РАЗЛИЧНЫХ ТИПОВ ФОКАЛЬНОЙ ЭПИЛЕПСИИ У ВЗРОСЛЫХ ПАЦИЕНТОВ. Экономика и социум, (10 (89)), 964-971.